RMD
ResMed Inc.
NYSE · USHealthcareMedical - Instruments & Supplies
$198.61-0.19%
Price as of Jul 20, 2026
RMD financials
ResMed Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $5.1B | $4.7B | $4.2B | $3.6B |
| Cost of revenue | $2.1B | $2.0B | $1.9B | $1.6B |
| Gross profit | $3.1B | $2.7B | $2.4B | $2.0B |
| Operating expenses | $1.4B | $1.3B | $1.2B | $1.0B |
| Operating income | $1.7B | $1.3B | $1.1B | $1.0B |
| Net income | $1.4B | $1.0B | $897.6M | $779.4M |
| EBITDA | $1.9B | $1.5B | $1.4B | $1.2B |
| Basic EPS | $9.55 | $6.94 | $6.12 | $5.34 |
| Diluted EPS | $9.51 | $6.92 | $6.09 | $5.30 |
| Balance sheet | ||||
| Cash & equivalents | $1.2B | $238.4M | $227.9M | $273.7M |
| Total assets | $8.2B | $6.9B | $6.8B | $5.1B |
| Total liabilities | $2.2B | $2.0B | $2.6B | $1.7B |
| Stockholders’ equity | $6.0B | $4.9B | $4.1B | $3.4B |
| Total debt | $851.8M | $873.9M | $1.6B | $917.5M |
| Net debt | -$357.6M | $635.6M | $1.4B | $643.8M |
| Cash flow | ||||
| Operating cash flow | $1.8B | $1.4B | $693.3M | $351.1M |
| Capital expenditure | -$89.9M | -$114.9M | -$134.0M | -$156.0M |
| Free cash flow | $1.7B | $1.3B | $559.3M | $195.1M |
| Dividends paid | -$310.9M | -$282.3M | -$258.3M | -$245.3M |
| Share repurchases | -$300.0M | -$150.0M | $0.00 | $0.00 |